Namerxin

Namerxin is a clinical-stage specialty pharmaceutical company based in Beijing, China, specializing in the development of complex long-acting injectable formulations. The company utilizes proprietary drug delivery technologies, including microspheres, liposomes, and nanocrystals, to create improved versions of established therapeutic agents. Namerxin's pipeline is primarily focused on chronic conditions within metabolic diseases, central nervous system disorders, and endocrinology. By leveraging the 505(b)(2) regulatory pathway, the company aims to enhance patient compliance and therapeutic outcomes through extended-release profiles. Its lead programs include long-acting versions of exenatide and risperidone, targeting large markets with significant unmet needs for convenient dosing.